Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M40.4Revenue $M1.8Net Margin (%)-1,046.6Z-Score5.1
Enterprise Value $M-3.0EPS $-1.5Operating Margin %-1,041.7F-Score2
P/E(ttm))0Cash Flow Per Share $-0.2Pre-tax Margin (%)-1,046.6Higher ROA y-yN
Price/Book1.010-y EBITDA Growth Rate %-45.5Quick Ratio17.8Cash flow > EarningsY
Price/Sales26.85-y EBITDA Growth Rate %-3.5Current Ratio17.8Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-23.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-24.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M18.9ROI % (ttm)-21.6Gross Margin Increase y-yN

Gurus Latest Trades with TSPT

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

TSPT is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


TSPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Roumell Asset Management, LLC10% Owner 2013-12-13Sell1,470$3.54-39.55 view
Roumell Asset Management, LLC10% Owner 2013-12-11Sell10,490$3.55-39.72 view
Roumell Asset Management, LLC10% Owner 2013-12-06Sell8,710$3.54-39.55 view
Roumell Asset Management, LLC10% Owner 2013-12-04Sell7,120$3.5-38.86 view
Roumell Asset Management, LLC10% Owner 2013-11-20Sell10,040$3.57-40.06 view
Roumell Asset Management, LLC10% Owner 2013-11-12Sell7,190$3.53-39.38 view
Roumell Asset Management, LLC10% Owner 2013-11-07Sell4,960$3.61-40.72 view
Roumell Asset Management, LLC10% Owner 2013-11-04Sell2,380$3.75-42.93 view
Roumell Asset Management, LLC10% Owner 2013-10-30Sell7,020$3.69-42.01 view
Roumell Asset Management, LLC10% Owner 2013-10-07Sell750$3.6-40.56 view

Press Releases about TSPT :

    Quarterly/Annual Reports about TSPT:

    News about TSPT:

    Articles On GuruFocus.com
    Transcept Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 15 2010 
    Transcept Pharmaceuticals Inc. Reports Operating Results (10-Q) May 14 2010 
    Transcept Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 16 2009 
    Transcept Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 14 2009 
    Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results Aug 14 2009 
    Transcept Pharmaceuticals Inc. Reports Operating Results (10-Q) May 15 2009 

    More From Other Websites
    TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events Sep 16 2014
    TRANSCEPT PHARMACEUTICALS INC Financials Aug 19 2014
    Q2 2014 Transcept Pharmaceuticals Inc. Earnings Release - Time Not Supplied Aug 11 2014
    TRANSCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 06 2014
    TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure Jul 03 2014
    TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jul 01 2014
    Paratek Appoints Michael Bigham as Chairman and CEO and Promotes Evan Loh to President and CMO Jul 01 2014
    Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement Jul 01 2014
    TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 16 2014
    Transcept Pharmaceuticals board declares special dividend of $1.33 per share May 14 2014
    Transcept Declares Special Cash Dividend Of $25 Million May 14 2014
    TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition May 05 2014
    Transcept Pharmaceuticals Reports First Quarter 2014 Financial Results May 05 2014
    TRANSCEPT PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 14 2014
    TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Mar 13 2014
    Transcept Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results Mar 13 2014
    TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K/A, Costs Associated with Exit or Disposal... Mar 05 2014
    TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 14 2014
    Transcept Pharmaceuticals Statement on Dismissal of Derivative Lawsuit Jan 13 2014
    Transcept Pharmaceuticals Statement on Dismissal of Derivative Lawsuit Jan 13 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK